Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · December 18, 2014

Ovarian Suppression Added to Tamoxifen Does Not Confer Additional Benefit in Premenopausal Breast Cancer

The New England Journal of Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

The New England Journal of Medicine
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
N. Engl. J. Med 2014 Dec 11;[EPub Ahead of Print], PA Francis et al for the SOFT Investigators and the International Breast Cancer Study Group

Further Reading